Drug catalog
Showing 92 of 92 drugs
| Drug | FDA status | Primary targets | Therapeutic indications |
|---|---|---|---|
| Abemaciclib | FDA Approved | CDK4_CYCLIN_D1, CDK4_CYCLIN_D3, CDK4_CYCLIN_D2, CDK6_CYCLIN_… | HER2-positive breast cancer, both monotherapy and combination therapy |
| Abrocitinib | FDA Approved | JAK1 | Atopic dermatitis |
| Acalabrutinib | FDA Approved | BTK | Mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma |
| Afatinib | FDA Approved | EGFR, ERBB2_HER2, ERBB4_HER4 | NSCLC (non-small cell lung cancer) and squamous NSCLC |
| Alectinib | FDA Approved | ALK, RET | Third-line Ph+ chronic myelogenous leukemia (CML) and CML with T315I mutations |
| Alpelisib | FDA Approved | PI3K | HR-positive, HER2-negative advanced breast cancer |
| Apatinib | NMPA Approved | KDR_VEGFR2 | Gastric cancer |
| Asciminib | FDA Approved | BCR_ABL, ABL1, ABL2_ARG | Ph+ CML |
| Avapritinib | FDA Approved | PDGFRA, PDGFRB | Gastrointestinal stromal tumors with a PDGFRα exon 18 mutation |
| Axitinib | FDA Approved | FLT1_VEGFR1, KDR_VEGFR2, FLT4_VEGFR3 | Advanced renal cell carcinoma |
| Baricitinib | FDA Approved | JAK1, JAK2 | Rheumatoid arthritis |
| Binimetinib | FDA Approved | MEK1, MEK2 | Melanoma with BRAF V600E or V600K mutations with encorafenib |
| Bosutinib | FDA Approved | BCR_ABL, ABL1, ABL2_ARG | Ph+ chronic myelogenous leukemia |
| Brigatinib | FDA Approved | ALK | ALK-positive NSCLC |
| Cabozantinib | FDA Approved | RET, KDR_VEGFR2 | Advanced medullary thyroid cancer, renal cell and hepatocellular carcinomas |
| Canertinib | FDA Trials Discontinued | ERBB2_HER2 | esophageal squamous cell carcinoma |
| Capivasertib | FDA Approved | AKT1, AKT2, AKT3 | HER2-negative advanced breast cancer |
| Capmatinib | FDA Approved | C_MET | NSCLC with MET exon 14 skipping mutations |
| Ceritinib | FDA Approved | ALK | ALK-positive NSCLC resistant to crizotinib |
| Cobimetinib | FDA Approved | MEK1, MEK2 | BRAF V600E or V600K mutation positive melanomas in combination with vemurafenib |
| Crizotinib | FDA Approved | ALK, ROS_ROS1 | ALK- or ROS1-postive NSCLC |
| Dabrafenib | FDA Approved | BRAF | BRAF mutation positive melanoma, NSCLC with BRAF V600E mutations, anaplastic thy… |
| Dacomitinib | FDA Approved | EGFR | EGFR-mutant NSCLC |
| Darovasertib | Phase III FDA Trials | PKCA, PKCB1, PKCB2, PKCD, PKCEPSILON, PKCETA, PKCG, PKCIOTA,… | metastatic uveal melanoma |
| Dasatinib | FDA Approved | BCR_ABL, ABL1, ABL2_ARG | Ph+ chronic myelogenous leukemia or acute lymphoblastic leukemia |
| Defactinib | FDA Approved | FAK_PTK2 | Pancreatic cancer, NSCLC and mesothelioma (in combination with pembrolizumab) |
| Deucravacitinib | FDA Approved | TYK2 | Psoriasis |
| Duvelisib | FDA Approved | PI3K | Relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic ly… |
| Encorafenib | FDA Approved | BRAF | BRAF V600E or V600K mutation positive melanoma with binimetinib; BRAF V600E muta… |
| Entrectinib | FDA Approved | TRKA | Solid tumors with NTRK fusion proteins, ROS1-positive NSCLC |
| Erdafitinib | FDA Approved | FGFR1 | Urothelial bladder cancer |
| Erlotinib | FDA Approved | EGFR | NSCLC, pancreatic cancer |
| Everolimus | FDA Approved | FKBP12, MTOR_FRAP1 | HER2-negative breast cancer, pancreatic neuroendocrine tumors, RCC, angiomyolipo… |
| Fedratinib | FDA Approved | JAK2 | Myelofibrosis |
| Fostamatinib | FDA Approved | SYK | Chronic immune thrombocytopenia |
| Futibatinib | FDA Approved | FGFR2 | Bile duct cancers (cholangiocarcinomas) with FGFR2 fusion proteins or other rear… |
| Gedatolisib | Phase III FDA Trials | PI3K, MTOR_FRAP1 | Hormone receptor–positive, HER2-negative metastatic breast cancer |
| Gefitinib | FDA Approved | EGFR | NSCLC with exon 19 deletions or exon 21 substitutions |
| Gilteritinib | FDA Approved | FLT3 | FLT3-mutation positive acute myeloid leukemia |
| Ibrutinib | FDA Approved | BTK | Chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, graf… |
| Idelalisib | FDA Approved | PI3K | Chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymph… |
| Imatinib | FDA Approved | BCR_ABL, ABL1, ABL2_ARG | Ph+ chronic myelogenous leukemia or acute lymphoblastic leukemia, aggressive sys… |
| Inavolisib | FDA Approved | PI3K | Hormone receptor (HR) positive, HER2-negative, PIK3CA-mutated breast cancer |
| Infigratinib | FDA Approval Withdrawn | FGFR2 | Cholangiocarcinomas with FGFR2 fusions or other rearrangement |
| Lapatinib | FDA Approved | EGFR, ERBB2_HER2 | HER2-positive breast cancer |
| Larotrectinib | FDA Approved | TRKA, TRKB, TRKC | Solid tumors with NTRK fusion proteins |
| Lazertinib | FDA Approved | EGFR | non-small cell lung cancer |
| Leniolisib | FDA Approved | PI3K | Activated phosphoinositide 3-kinase delta syndrome |
| Lenvatinib | FDA Approved | FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2, RET | Differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, e… |
| Lorlatinib | FDA Approved | ALK | ALK-positive NSCLC |
| Midostaurin | FDA Approved | FLT3 | FLT3 mutation positive AML, mastocytosis, mast cell leukemia |
| Mitapivat | FDA Approved | PK | hemolytic anemia |
| Mobocertinib | FDA Approval Withdrawn | EGFR | NSCLC with EGFR-positive exon 20 insertions |
| Neratinib | FDA Approved | ERBB2_HER2 | HER2-positive breast cancer |
| Netarsudil | FDA Approved | ROCK1, ROCK2 | Glaucoma |
| Nilotinib | FDA Approved | BCR_ABL, ABL1, ABL2_ARG | Ph+ chronic myelogenous leukemia |
| Nintedanib | FDA Approved | FGFR1, FGFR2, FGFR3 | Idiopathic pulmonary fibrosis |
| Osimertinib | FDA Approved | EGFR | NSCLC with exon 19 or exon 21 substitutions (L858R) or T790M mutations |
| Pacritinib | FDA Approved | JAK2 | Myelofibrosis |
| Palbociclib | FDA Approved | CDK4_CYCLIN_D1, CDK4_CYCLIN_D3, CDK4_CYCLIN_D2, CDK6_CYCLIN_… | Breast cancer (HER2-positive or negative) combination therapy |
| Paxalisib | FDA Phase III Trials to begin | PI3K, MTOR_FRAP1 | Brain cancers |
| Pazopanib | FDA Approved | FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2 | Renal cell carcinoma, soft tissue sarcomas |
| Pemigatinib | FDA Approved | FGFR2 | Advanced cholangiocarcinoma with FGFR2 fusions or rearrangements |
| Pexidartinib | FDA Approved | FMS | Tenosynovial giant cell tumors |
| Pirtobrutinib | FDA Approved | BTK | Mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma |
| Ponatinib | FDA Approved | BCR_ABL, ABL1, ABL2_ARG | Ph+ chronic myelogenous leukemia, acute lymphoblastic leukemia |
| Pralsetinib | FDA Approved | RET | RET-fusion protein NSCLC, RET mutant medullary thyroid cancer, RET fusion thyroi… |
| Quizartinib | FDA Approved | FLT3 | FLT3 internal tandem duplication positive acute myelogenous leukemia in combinat… |
| Rabusertib | FDA trials Discontinued after Phase II | CHK1 | Pancreatic cancer, non-small cell lung carcinoma |
| Regorafenib | FDA Approved | FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2 | Colorectal cancer, hepatocellular carcinoma, gastrointestinal stromal tumors |
| Remibrutinib | FDA Phase III Trials | BTK | Chronic spontaneous urticaria |
| Repotrectinib | FDA Approved | ROS_ROS1 | ROS1-positive NSCLC |
| Ribociclib | FDA Approved | CDK4_CYCLIN_D1, CDK4_CYCLIN_D3, CDK4_CYCLIN_D2, CDK6_CYCLIN_… | Breast cancer (HER2-positive or negative) combination therapy |
| Ripretinib | FDA Approved | C_KIT, PDGFRA, PDGFRB | Fourth-line treatment for gastrointestinal stromal tumors |
| Ruxolitinib | FDA Approved | JAK1, JAK2, JAK3, TYK2 | Myelofibrosis, polycythemia vera, graft vs. host disease, atopic dermatitis (app… |
| Selpercatinib | FDA Approved | RET | RET fusion NSCLC, RET fusion solid tumors, RET fusion thyroid cancers and RET mu… |
| Selumetinib | FDA Approved | MEK1, MEK2 | Neurofibromatosis type I |
| Sirolimus | FDA Approved | FKBP12, MTOR_FRAP1 | Kidney transplant, lymphangioleiomyomatosis |
| Sorafenib | FDA Approved | FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2 | Hepatocellular carcinoma, renal cell carcinoma, differentiated thyroid cancer |
| Sunitinib | FDA Approved | KDR_VEGFR2 | Gastrointestinal stromal tumors, renal cell carcinoma, pancreatic neuroendocrine… |
| Temsirolimus | FDA Approved | FKBP12, MTOR_FRAP1 | Advance renal cell carcinoma |
| Tenalisib | FDA Phase I Trials Completed | PI3K | T cell lymphomas |
| Tepotinib | FDA Approved | C_MET | MET-mutant NSCLC |
| Tivozanib | FDA Approved | KDR_VEGFR2 | Third-line treatment of renal cell carcinoma |
| Tofacitinib | FDA Approved | JAK3 | Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis |
| Trametinib | FDA Approved | MEK1, MEK2 | Melanoma with BRAF V600E or V600K mutations with dabrafenib; NSCLC with BRAF V60… |
| Tucatinib | FDA Approved | ERBB2_HER2 | HER2-positive breast cancer and colon cancer |
| Umbralisib | FDA Approval Withdrawn | CK1EPSILON, PI3K | Marginal zone lymphoma, follicular lymphoma |
| Upadacitinib | FDA Approved | JAK1 | Second-line treatment for rheumatoid arthritis, psoriatic arthritis, atopic derm… |
| Vandetanib | FDA Approved | KDR_VEGFR2 | Medullary thyroid cancer |
| Vemurafenib | FDA Approved | BRAF | BRAF V600E or V600K mutation positive melanoma with cobimetinib; Chester-Erdheim… |
| Zanubrutinib | FDA Approved | BTK | Mantle cell lymphoma |